Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - October 2019, Vol 12, No 5

The October issue of The Oncology Nurse-APN/PA (TON) is filled with important news and insights for today’s oncology nurse. We begin our coverage with a profile of the Allegheny Health Network Cancer Institute, Pittsburgh, PA, as we speak with Anna Vioral, PhD, Med, RN, OCN, BMTCN, who discusses her professional responsibilities at the center, and her recent appointment to the Board of Directors of the Oncology Nursing Certification Corporation (see page 1).
Ovarian cancer is a very difficult disease to diagnose and is the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States. A woman’s risk for developing ovarian cancer in her lifetime is approximately 1 in 78, and her lifetime risk for dying of the disease is approximately 1 in 108. The disease was previously thought to begin in the ovaries, but recent research suggests that many ovarian cancers may actually start in the distal end of the fallopian tubes. The following provides key statistics and other helpful information regarding ovarian cancer.
Allegheny Health Network (AHN) is a large, integrated healthcare system that provides care to patients throughout western Pennsylvania. As part of this network, the AHN Cancer Institute (AHNCI), offers personalized, high-quality cancer care to patients at >20 locations in and around the Pittsburgh area. The institute uses the latest, most effective anticancer therapies, and through its partnership with Johns Hopkins Kimmel Cancer Center, can offer patients access to clinical trials as well as combined expertise when second opinions are necessary.
Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected.
Anaheim, CA—Good communication skills are essential for providing high-quality cancer care. However, communicating effectively becomes more complicated when patients have received a poor prognosis. At the 2019 Oncology Nursing Society 44th Annual Congress, Andria Caton, BSN, RN, OCN, CHPN, Assistant Nurse Manager, Northeast Georgia Medical Center, Gainesville, provided oncology nurses with strategies for improving communication with patients and their families during end-of-life care.
San Francisco, CA—Patients can be taught via neurofeedback to modify their brainwave activity and decrease the sensations of chemotherapy-induced peripheral neuropathy (CIPN), according to Sarah Prinsloo, PhD, LMFT, LPC, Assistant Professor, Department of Palliative, Rehabilitation, and Integrative Medicine, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX.
  • New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
  • Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
  • Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
San Francisco, CA—The human papillomavirus (HPV) has changed the field of head and neck cancer, and HPV now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising in the United States, so is patient curiosity about what sets this cancer apart from other malignancies.
San Francisco, CA—Adolescent and young adult (AYA) patients with cancer consistently indicate the need for better communication from their oncology providers on matters concerning sexual health. Despite misconceptions that the topic may embarrass them or fall on deaf ears, surveys show that AYAs actually want to talk to their providers about topics such as dating, safe sex practices during treatment, contraception, body image, sexuality, fertility, and psychosexual adjustment.
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with ROS1 rearrangement, induced a response in 9 of 11 patients with TKI-naïve, ROS1-fusion–positive non–small-cell lung cancer (NSCLC).
Page 1 of 2
Results 1 - 10 of 14